FDA Approves Spero Therapeutics' UTEBZI, First Oral Carbapenem for Complicated UTIs
SPRO sits 27% above its 52-week low of $1.8 on elevated volume (7.2× avg).
Summary
The FDA has approved Spero Therapeutics' UTEBZI (tebipenem pivoxil) tablets for the treatment of complicated urinary tract infections. This marks the first oral carbapenem therapy to receive FDA approval, representing a significant milestone for the company. The approval follows the confirmed PDUFA date of June 18, 2026, which was announced in the company's Q1 2026 results on May 13, 2026. This de-risks Spero's lead product and opens a new market opportunity.
At the time of this announcement, SPRO was trading at $2.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $132.6M. The 52-week trading range was $1.80 to $3.22. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.